Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.

2.50
Hdl Handle:
http://hdl.handle.net/10029/621659
Title:
Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
Authors:
Fortner, Renée T; Schock, Helena; Le Cornet, Charlotte; Hüsing, Anika; Vitonis, Allison F; Johnson, Theron S; Fichorova, Raina N; Fashemi, Titilayo; Yamamoto, Hidemi S; Tjønneland, Anne; Hansen, Louise; Overvad, Kim; Boutron-Ruault, Marie-Christine; Kvaskoff, Marina; Severi, Gianluca; Boeing, Heiner; Trichopoulou, Antonia; Papatesta, Eleni-Maria; La Vecchia, Carlo; Palli, Domenico; Sieri, Sabina; Tumino, Rosario; Sacerdote, Carlotta; Mattiello, Amalia; Onland-Moret, N Charlotte; Peeters, Petra H; Bueno-de-Mesquita, H B As; Weiderpass, Elisabete; Quirós, J Ramón; Duell, Eric J; Sánchez, Maria-Jose; Navarro, Carmen; Ardanaz, Eva; Larrañaga, Nerea; Nodin, Björn; Jirström, Karin; Idahl, Annika; Lundin, Eva; Khaw, Kay-Tee; Travis, Ruth C; Gunter, Marc; Johansson, Mattias; Dossus, Laure; Merritt, Melissa A; Riboli, Elio; Terry, Kathryn L; Cramer, Daniel W; Kaaks, Rudolf
Abstract:
CA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.
Citation:
Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. 2018, 142 (7):1355-1360 Int. J. Cancer
Journal:
Int J Cancer 2087; 142(7):1355-60
Issue Date:
1-Apr-2018
URI:
http://hdl.handle.net/10029/621659
DOI:
10.1002/ijc.31164
PubMed ID:
29159934
Type:
Article
Language:
en
ISSN:
1097-0215
Appears in Collections:
Miscellaneous

Full metadata record

DC FieldValue Language
dc.contributor.authorFortner, Renée Ten
dc.contributor.authorSchock, Helenaen
dc.contributor.authorLe Cornet, Charlotteen
dc.contributor.authorHüsing, Anikaen
dc.contributor.authorVitonis, Allison Fen
dc.contributor.authorJohnson, Theron Sen
dc.contributor.authorFichorova, Raina Nen
dc.contributor.authorFashemi, Titilayoen
dc.contributor.authorYamamoto, Hidemi Sen
dc.contributor.authorTjønneland, Anneen
dc.contributor.authorHansen, Louiseen
dc.contributor.authorOvervad, Kimen
dc.contributor.authorBoutron-Ruault, Marie-Christineen
dc.contributor.authorKvaskoff, Marinaen
dc.contributor.authorSeveri, Gianlucaen
dc.contributor.authorBoeing, Heineren
dc.contributor.authorTrichopoulou, Antoniaen
dc.contributor.authorPapatesta, Eleni-Mariaen
dc.contributor.authorLa Vecchia, Carloen
dc.contributor.authorPalli, Domenicoen
dc.contributor.authorSieri, Sabinaen
dc.contributor.authorTumino, Rosarioen
dc.contributor.authorSacerdote, Carlottaen
dc.contributor.authorMattiello, Amaliaen
dc.contributor.authorOnland-Moret, N Charlotteen
dc.contributor.authorPeeters, Petra Hen
dc.contributor.authorBueno-de-Mesquita, H B Asen
dc.contributor.authorWeiderpass, Elisabeteen
dc.contributor.authorQuirós, J Ramónen
dc.contributor.authorDuell, Eric Jen
dc.contributor.authorSánchez, Maria-Joseen
dc.contributor.authorNavarro, Carmenen
dc.contributor.authorArdanaz, Evaen
dc.contributor.authorLarrañaga, Nereaen
dc.contributor.authorNodin, Björnen
dc.contributor.authorJirström, Karinen
dc.contributor.authorIdahl, Annikaen
dc.contributor.authorLundin, Evaen
dc.contributor.authorKhaw, Kay-Teeen
dc.contributor.authorTravis, Ruth Cen
dc.contributor.authorGunter, Marcen
dc.contributor.authorJohansson, Mattiasen
dc.contributor.authorDossus, Laureen
dc.contributor.authorMerritt, Melissa Aen
dc.contributor.authorRiboli, Elioen
dc.contributor.authorTerry, Kathryn Len
dc.contributor.authorCramer, Daniel Wen
dc.contributor.authorKaaks, Rudolfen
dc.date.accessioned2018-03-20T14:18:24Z-
dc.date.available2018-03-20T14:18:24Z-
dc.date.issued2018-04-01-
dc.identifier.citationOvarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. 2018, 142 (7):1355-1360 Int. J. Canceren
dc.identifier.issn1097-0215-
dc.identifier.pmid29159934-
dc.identifier.doi10.1002/ijc.31164-
dc.identifier.urihttp://hdl.handle.net/10029/621659-
dc.description.abstractCA125 is the best ovarian cancer early detection marker to date; however, sensitivity is limited and complementary markers are required to improve discrimination between ovarian cancer cases and non-cases. Anti-CA125 autoantibodies are observed in circulation. Our objective was to evaluate whether these antibodies (1) can serve as early detection markers, providing evidence of an immune response to a developing tumor, and (2) modify the discriminatory capacity of CA125 by either masking CA125 levels (resulting in lower discrimination) or acting synergistically to improve discrimination between cases and non-cases. We investigated these objectives using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort (EPIC) including 250 cases diagnosed within 4 years of blood collection and up to four matched controls. Circulating CA125 antigen and antibody levels were quantified using an electrochemiluminescence assay. Adjusted areas under the curve (aAUCs) by 2-year lag-time intervals were calculated using conditional logistic regression calibrated toward the absolute risk estimates from a pre-existing epidemiological risk model as an offset-variable. Anti-CA125 levels alone did not discriminate cases from controls. For cases diagnosed <2 years after blood collection, discrimination by CA125 antigen was suggestively higher with higher anti-CA125 levels (aAUC, highest antibody tertile: 0.84 [0.76-0.92]; lowest tertile: 0.76 [0.67-0.86]; phet = 0.06). We provide the first evidence of potentially synergistic discrimination effects of CA125 and anti-CA125 antibodies in ovarian early detection. If these findings are replicated, evaluating CA125 in the context of its antibody may improve ovarian cancer early detection.en
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleOvarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.en
dc.typeArticleen
dc.identifier.journalInt J Cancer 2087; 142(7):1355-60en

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.